ASHP retweeted
CMS cuts Medicare physician payments for 2027. modernhealthcare.com/politic…
ASHP retweeted
PBM crackdown enters new chapter as new mandates approach. modernhealthcare.com/insuran…
CVS is reportedly discussing plans to spin off its retail pharmacy business, a shocking retreat for the country’s largest drugstore chain bloomberg.com/news/articles/…
ASHP retweeted
In celebration of #PharmacyWeek, ASHP is highlighting the power of collaboration across the pharmacy profession. In the latest episode of our Insights & Connections podcast, ASHP CEO Sam Calabrese sits down with APhA CEO Michael Hogue to discuss how working together can better support pharmacy professionals, advance patient care, and strengthen the future of pharmacy. Listen to the conversation: hubs.ly/Q04C2Zzs0 @pharmacists
ASHP retweeted
Ever wondered where a career in hospital and health-system pharmacy can take you?
To celebrate #PharmacyWeek, we sat down with father-daughter duo Daniel Good, MS, RPh, FASHP, and Megan Good, PharmD on the We’re Your Pharmacist podcast. From high school STEM programs to specialized hospital clinical practice, they share how shadowing, mentorship, and hands-on learning shaped their pharmacy journeys.
If you’re a student considering healthcare or looking for guidance as you navigate pharmacy school, watch the video below and listen to the full podcast episode! hubs.ly/Q04CcCtM0
A federal judge sides with 25 states and the District of Columbia, which had argued that the new Medicaid work requirement rule would force medically frail people to clear unnecessary hurdles to maintain government-funded health insurance coverage. nbcnews.com/health/health-ca…
Working-age U.S. adults without health insurance rose in 2026, a new survey finds.
This trend is likely to continue: In 2027, major Medicaid cuts and Affordable Care Act marketplace restrictions will make it even harder for Americans to access coverage. trib.al/OCRTtGC
GSK has won FDA approval for its hepatitis B drug, which extended functional cures to far more patients than previous methods. trib.al/yQ7jwoh
ASHP retweeted
The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. @AndreaCercek @coloncancermike @CCAlliance
medpagetoday.com/hematologyo…
The Trump administration is proceeding with a plan to allow compounding pharmacies to produce certain peptides trib.al/UgAjWTZ
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight reut.rs/4jJM9gI reut.rs/4jJM9gI
ASHP retweeted
US advances first government-funded trials of psychedelic drug ibogaine reuters.com/legal/litigation…
People 34 and younger may be less likely to develop shingles than previous generations, new data suggests, thanks in part to widespread chickenpox vaccination. nbcnews.com/health/health-ne…
At least one million US seniors will be forced to switch health plans next year as the largest Medicare Advantage providers cut benefits and discontinue some offerings. bloomberg.com/news/articles/…
Refugees, asylum seekers and some other immigrants with legal status will lose Medicaid coverage October 1 bloomberg.com/news/articles/…
ASHP retweeted
The Centers for Medicare & Medicaid Services estimates the weighted average premium for Medicare Advantage (MA) plans to fall more than 16% next year. reuters.com/legal/litigation…
ASHP retweeted
The Centers for Medicare & Medicaid Services estimates the weighted average premium for Medicare Advantage (MA) plans to fall more than 16% next year. reuters.com/legal/litigation…
Today in managed care: Healio reports, “The FDA approved an expanded indication for baricitinib, a once daily oral JAK inhibitor, for teens aged 12 and older with severe alopecia areata.” This “approval marks the second JAK inhibitor treatment for adolescents with severe alopecia areata, which can be more severe and extensive with early onset.”
healio.com/news/dermatology/…
More than 20% of all cancer centers report shortages of five or more different medicines trib.al/rdvd6lX
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial reut.rs/4xDVtGZ reut.rs/4xDVtGZ








